MedTrace Logo

Patient Preference for Subcutaneous vs. Intravenous Immune Therapy

NCT07223424 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 880

Last updated 2026-04-16

No results posted yet for this study

Summary

The study will evaluate patient and Health Care Professional- reported preference for Subcutaneous (SC) compared with IV nivolumab administration or similarly for SC compared with IV pembrolizumab.

Conditions

Interventions

DRUG

nivolumab

IV nivolumab (480mg Q4W), SC nivolumab (1200mg Q4W)

DRUG

pembrolizumab

IV pembrolizumab (400mg Q6W) or SC pembrolizumab (790mg Q6W)

Sponsors & Collaborators

  • Diwakar Davar

    lead OTHER

Principal Investigators

  • Diwakar J Davar, MD · UPMC Hillman Cancer Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-11-04
Primary Completion
2030-11-30
Completion
2030-11-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07223424 on ClinicalTrials.gov